Free Trial

Entasis Therapeutics (ETTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
800 shs
Average Volume
239,104 shs
Market Capitalization
$104.80 million
P/E Ratio
Dividend Yield
Price Target
ETTX stock logo

About Entasis Therapeutics Stock (NASDAQ:ETTX)

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

ETTX Stock News Headlines

Entasis Flat on Data
See More Headlines
Receive ETTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical Preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$7 million
Book Value
$0.66 per share


Free Float
Market Cap
$104.80 million
Not Optionable
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Manoussos Perros Ph.D. (Age 54)
    Pres, CEO & Director
    Comp: $1.09M
  • Dr. Ruben Tommasi (Age 56)
    Chief Scientific Officer
    Comp: $704.98k
  • Dr. David Altarac M.D. (Age 61)
    MPA, Chief Medical Officer
    Comp: $801.88k
  • Ms. Kristie Wagner (Age 55)
    Interim VP and Interim Principal Financial & Accounting Officer
  • Ms. Elizabeth M. KeileyMs. Elizabeth M. Keiley (Age 56)
    Gen. Counsel
  • Dr. John Patrick Mueller Ph.D. (Age 62)
    Chief Devel. Officer
  • Dr. Matthew Ronsheim Ph.D. (Age 50)
    Chief Pharmaceutical Sciences & Manufacturing Officer
  • Ms. Anna Diaz Triola MBA (Age 47)
    Chief Commercial Officer

ETTX Stock Analysis - Frequently Asked Questions

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.26). During the same quarter in the prior year, the firm posted ($0.37) EPS.

What other stocks do shareholders of Entasis Therapeutics own?
When did Entasis Therapeutics IPO?

Entasis Therapeutics (ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

This page (NASDAQ:ETTX) was last updated on 5/29/2024 by Staff

From Our Partners